Use of inhaled nitric oxide (iNO) among pediatric patients has increased since 2005 and, during a 10 - year time period, mortality rates dropped modestly as the therapeutic approach was applied to a broader range of
health ailments, according to an observational analysis
presented Feb. 26, 2018 during the 47th Critical Care Congress.
The major problems faced in processing such critical data are: coverage against previously existing diseases /
ailments; Claim history (with details of all previous claims) and
present health status of the proposer or insured.